Senseonics announced today that it filed for CE mark for its Eversense 365 continuous glucose monitor (CGM) system.
Senseonics has filed to obtain CE Mark registration for its one-year continuous glucose monitoring (CGM) system, Eversense ...
Eversense 365 is the world’s first and only one year CGM, which was approved by the United States (US) Food and Drug Administration in September of 2024 and launched across the country in October of ...
Medha N. Munshi, MD, a geriatrician and endocrinologist at Beth Israel Deaconess Medical Center, has dedicated her career to ...
Insulin pump market growth is propelled by advancements in technology, rising global diabetes prevalence, and increased demand for precision diabetes management.New Delhi, Feb. 06, 2025 (GLOBE ...
Families want nurse or staff to monitor apps remotely in case of urgent alarms; schools cite shrinking budgets and internet ...
Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...
Key market drivers of the Insulin Pen and Pump market include the rising prevalence of diabetes, advancements in insulin delivery technologies ...
Hosted on MSN8d
Beta Bionics raises $204m to kickstart medtech IPO seasonAn artificial pancreas, also known as a closed-loop system, uses communication between an insulin pump and a continuous glucose monitor (CGM) to automatically adjust insulin levels in response to ...
Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced compelling ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results